As an ATP-competitive PI3K/mTOR dual inhibitor, gedatolisib (PF-04691502) has been utilized to inhibit tumor growth and CSC proliferation in both in vitro and in vivo colon cancer models [179]. This evidence concerns the gene MTOR and malignant colon neoplasm.